Sign in

CIK 0001348362

  • Non-accelerated filer
  • Smaller reporting company

Lexaria Bioscience Corp.

Sign in to watch
Ticker
LEXX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Aug 31
Incorporated
NV
Entity type
Operating
EIN
202000871
Phone
+1 250-765-6424
Business address
100 - 740 MCCURDY ROAD, KELOWNA, British Columbia, Canada, V1X 2P7
Former names
Lexaria Corp., LEXARIA CORP.
  1. 4 Grant or award Director acquired 114,286 shares (grant or award)
  2. 4 Grant or award President acquired 252,000 shares (grant or award)
  3. 4 Open-market buy CEO bought 20,000 shares at an average $0.13 ($2,515)
  4. 4 Open-market buy CEO bought 2,500 shares at $0.15 ($363)
  5. 4 Open-market buy CEO bought 5,100 shares at $0.13 ($653)
  6. 4 Open-market buy CEO bought 27,637 shares at an average $0.13 ($3,545)
  7. 4 Open-market buy CEO bought 19,800 shares at an average $0.13 ($2,494)
  8. 4 Open-market buy CEO bought 13,340 shares at an average $0.13 ($1,774)
  9. 4 Open-market buy CEO bought 10,000 shares at $0.15 ($1,500)
  10. 4 Open-market buy CEO bought 450,000 shares at $0.06 ($27,000)
  11. 4 Open-market buy CEO bought 5,000 shares at $0.13 ($645)
  12. 4 Open-market buy CEO bought 24,083 shares at an average $0.12 ($2,910)
  13. 4 Open-market buy CEO bought 7,500 shares at an average $0.12 ($932)
  14. 4 Open-market buy CEO bought 7,000 shares at $0.14 ($952)
  15. 4 Open-market buy CEO bought 62,305 shares at an average $0.12 ($7,445)
  16. 4 Open-market buy CEO bought 12,000 shares at an average $0.11 ($1,360)
  17. 4 Open-market buy CEO bought 59,000 shares at an average $0.09 ($5,485)
  18. 4 Open-market buy President bought 210,000 shares at $0.10 ($21,000)
  19. 4 Insider Changes in Ownership
  20. 4 Open-market buy President bought 17,000 shares at an average $0.10 ($1,650)

Page 8 of 21 · 420 filings